Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.46 |
| ▸ | ADH1C | P00326 | 1/20 | 0.46 |
| ▸ | ADH1A | P07327 | 1/20 | 0.46 |
| ▸ | ADH4 | P08319 | 1/20 | 0.46 |
| ▸ | ADH7 | P40394 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL735582 | 0.98 | ADH1B (0.43) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL736323 | 0.93 | — | — | |
| SCHEMBL735483 | 0.87 | — | — | |
| SCHEMBL735850 | 0.86 | SAT1 (0.45) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL11594234 | 0.85 | ADH1B (0.54) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL738708 | 0.84 | SAT1 (0.47) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL893878 | 0.80 | SAT1 (0.58) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL737171 | 0.80 | EPHX1 (0.50) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL736391 | 0.79 | SAT1 (0.47) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL4470765 | 0.79 | SIGMAR1 (0.41) | ADH1BADH1CADH1AADH4ADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275412-A1 | Indole and benzimidazole derivatives | Novartis Vaccines and Diagnostics, Inc. (US) | 2011-01-19 | — | — | EP | claimed |
| US-7608723-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-1H-benzimidazol-2-yl)-2-methylpropyl]-4-chlorobenzamide;kinesin spindle protein modulators; anticarcinogenic agents; in vivo stability, bio-availability; diagnosis/medical/;antitumor agents hyperplasia; restinosis; antiinflammatory agents; cardiac hypertrophy | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-10-27 | — | — | US | claimed |
| US-20090028858-A1 | SUBSTITUTED QUINOLINE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOTICS, INC. | 2009-01-29 | — | — | US | claimed |
| US-20080317744-A1 | Indole and Benzimidazole Derivatives | CHIRON CORPORATION (US) | 2008-12-25 | — | — | US | claimed |
| US-7452996-B2 | Substituted quinoline derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-11-18 | — | — | US | claimed |
| EP-1753723-B1 | SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1807399-A2 | INDOLE AND BENZIMIDAZOLE DERIVATIVES | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-07-18 | — | — | EP | claimed |
| EP-1753723-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| WO-2006049835-A2 | INDOLE AND BENZIMIDAZOLE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-05-11 | — | — | WO | claimed |
| US-20060084687-A1 | Indole and benzimidazole derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2006-04-20 | — | — | US | claimed |
| WO-2005113507-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2005-12-01 | — | — | WO | claimed |
| US-20050261337-A1 | N-(3-aminopropyl)-N- [1-(3-benzylquinolin-2-yl)- 2-methylpropyl]-3-fluoro-4-methylbenzamide; cancer; disorder mediated, at least in part by kinesin-related proteins | WANG WEIBO | 2005-11-24 | — | — | US | claimed |
| US-6768024-B1 | CONTROLLING OBESITY, SEXUAL DYSFUNCTION OR INFLAMMATION | LION BIOSCIENCE AG (DE) | 2004-07-27 | — | — | US | claimed |
| WO-2002012166-A2 | TRIAMINE DERIVATIVE MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USING SAME | LION BIOSCIENCE AG (DE) | 2002-02-14 | — | — | WO | claimed |
| CN-105407729-B | Wrap polyamine-containing composition and method | 库扎环球有限责任公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-105407729-A | Compositions and methods comprising a polyamine | CURZA GLOBAL LLC | 2016-03-16 | — | — | CN | disclosed |
| EP-1717230-B1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | disclosed |
| WO-2002012166-A2 | TRIAMINE DERIVATIVE MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USING SAME | LION BIOSCIENCE AG (DE) | 2002-02-14 | — | — | WO | disclosed |
| US-5981557-A | HAVING IMPROVING EFFECTS ON THE DYSMOTILITY IN THE GASTROINTESTINAL TRACT | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-09 | — | — | US | disclosed |
| EP-0870765-A1 | AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090028858-A1 | SUBSTITUTED QUINOLINE DERIVATIVES | ABCG2, ABCB1, UGT2B7 | ADH1B 659/4885ADH1C 3309/4885ADH1A 1397/4885 |
| US-20050261337-A1 | N-(3-aminopropyl)-N- [1-(3-benzylquinolin-2-yl)- 2-methylpropyl]-3-fluoro-4-methylbenzamide; cancer; disorder mediated, at least in part by kinesin-related proteins | KIF5B, KIF2C, KIF5C | ADH1B 2345/4885ADH1C 2816/4885ADH1A 1542/4885 |
| US-20060084687-A1 | Indole and benzimidazole derivatives | IDO1, IDO2, AADAC | ADH1B 839/4885ADH1C 2343/4885ADH1A 718/4885 |
| US-20080317744-A1 | Indole and Benzimidazole Derivatives | IDO1, IDO2, AADAC | ADH1B 839/4885ADH1C 2343/4885ADH1A 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.